Form of diagnosed psoriasis other than chronic plaque psoriasis (i.e. guttate, erythrodermic, pustular)
Diagnosis of other active, ongoing skin diseases or skin infections that may interfere with examination of psoriasis lesions
Ongoing use of other psoriasis treatment including but not limited to topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy. The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies
Use of oral estrogen therapy, excluding oral contraceptive pills
Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception.
Patients unwilling to limit exposure to UV light
Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk
Patients with disorders of calcium metabolism and/or hypercalcemia
Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)
History of allergy to any component of the IP

NCT03506477_exc_T1
Condition
psoriasis
NCT03506477_exc_T2
Negation
other than
NCT03506477_exc_T3
Condition
chronic plaque psoriasis
NCT03506477_exc_T4
Qualifier
guttate
NCT03506477_exc_T5
Qualifier
erythrodermic
NCT03506477_exc_T6
Qualifier
pustular
NCT03506477_exc_T7
Scope
other than chronic plaque psoriasis
NCT03506477_exc_T8
Scope
guttate, erythrodermic, pustular
NCT03506477_exc_T9
Qualifier
active
NCT03506477_exc_T10
Temporal
ongoing
NCT03506477_exc_T11
Condition
skin diseases
NCT03506477_exc_T12
Condition
skin infections
NCT03506477_exc_T14
Scope
skin diseases or skin infections
NCT03506477_exc_T15
Procedure
treatment
NCT03506477_exc_T16
Condition
psoriasis
NCT03506477_exc_T17
Drug
pical o rticosteroids,
NCT03506477_exc_T18
Drug
systemic corticosteroids
NCT03506477_exc_T19
Drug
topical medications
NCT03506477_exc_T20
Drug
coal tar
NCT03506477_exc_T21
Drug
al o dications f
NCT03506477_exc_T22
Drug
biologic medications
NCT03506477_exc_T24
Procedure
UV therapy
NCT03506477_exc_T25
Temporal
Ongoing
NCT03506477_exc_T26
Scope
topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy
NCT03506477_exc_T27
Procedure
oral estrogen therapy
NCT03506477_exc_T28
Drug
oral contraceptive pills
NCT03506477_exc_T29
Negation
excluding
NCT03506477_exc_T31
Mood
unwilling
NCT03506477_exc_T32
Procedure
limit exposure to UV light
NCT03506477_exc_T34
Condition
disorders of calcium metabolism
NCT03506477_exc_T35
Condition
hypercalcemia
NCT03506477_exc_T37
Condition
allergy
NCT03506477_exc_T38
Drug
any component of the IP